{
    "Clinical Trial ID": "NCT00072293",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Axillary Dissection",
        "  Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.",
        "  Axillary lymph node dissection: Axillary lymph node dissection",
        "INTERVENTION 2: ",
        "  No Axillary Dissection",
        "  Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.",
        "  No axillary lymph node dissection: Therapeutic conventional surgery"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma",
        "  Largest tumor lesion  5 cm",
        "  Palpable or nonpalpable breast lesion",
        "  Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions",
        "  Prior (preoperative) or planned (intraoperative) sentinel node biopsy required",
        "  At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension",
        "  No clinical evidence of distant metastases",
        "  No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:",
        "  Skeletal pain of unknown cause",
        "  Elevated alkaline phosphatase",
        "  Bone scan showing hot spots",
        "  No palpable axillary lymph node(s)",
        "  No Paget's disease without invasive cancer",
        "  Hormone receptor status:",
        "  Estrogen receptor and progesterone receptor known",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  Any age",
        "  Sex",
        "  Female",
        "  Menopausal status",
        "  Any status",
        "  Performance status",
        "  Not specified",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  Not specified",
        "  Hepatic",
        "  See Disease Characteristics",
        "  Renal",
        "  Not specified",
        "  Other",
        "  Not pregnant or nursing",
        "  No other prior or concurrent malignancy except the following:",
        "  Adequately treated basal cell or squamous cell skin cancer",
        "  Adequately treated carcinoma in situ of the cervix",
        "  Adequately treated in situ melanoma",
        "  Contralateral or ipsilateral carcinoma in situ of the breast",
        "  No psychiatric, addictive, or other disorder that may compromise ability to give informed consent",
        "  Geographically accessible for follow-up",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  Not specified",
        "  Chemotherapy",
        "  Not specified",
        "  Endocrine therapy",
        "  Not specified",
        "  Radiotherapy",
        "  Not specified",
        "  Surgery",
        "  See Disease Characteristics",
        "  Other",
        "  No prior systemic therapy for breast cancer",
        "  More than 1 year since prior chemopreventive agent"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  5-year Disease-Free Survival",
        "  Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to first evidence of invasive relapse at any site, second primary tumor (contralateral or non-breast) or death.",
        "  Time frame: 5-year estimate reported after a median follow-up of 60 months",
        "Results 1: ",
        "  Arm/Group Title: Axillary Dissection",
        "  Arm/Group Description: Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.",
        "  Axillary lymph node dissection: Axillary lymph node dissection",
        "  Overall Number of Participants Analyzed: 464",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  84.4",
        "Results 2: ",
        "  Arm/Group Title: No Axillary Dissection",
        "  Arm/Group Description: Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.",
        "  No axillary lymph node dissection: Therapeutic conventional surgery",
        "  Overall Number of Participants Analyzed: 467",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  87.8"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/447 (0.22%)",
        "  Post-operative infection (L.axilla) 1/447 (0.22%)",
        "Adverse Events 2:",
        "  Total: 0/453 (0.00%)",
        "  Post-operative infection (L.axilla) 0/453 (0.00%)"
    ]
}